Tag: bluescript ii
Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies
Greater than 100 monoclonal antibodies (mAbs) have been accepted by FDA. The mechanism of motion (MoA) includes in neutralization of a selected goal by way of the Fab area and Fc effector features by Fc area, whereas the latter embody complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent mobile phagocytosis (ADCP). ADCP has been acknowledged one of the…
Read MoreRegulation of Th1 T Cell Differentiation by Iron via Upregulation of T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3)
Iron performs an essential position in host-pathogen interactions, in being an important ingredient for each pathogen and host metabolism, but in addition by impacting immune cell differentiation and anti-microbial effector pathways. Iron has been implicated to have an effect on the differentiation of T lymphocytes throughout irritation, nevertheless, up to now the underlying mechanism remained…
Read More